Showing results (81-90 of 309) with videos related to

Sort By:
Pageof 31
Bladder Cancer (Amsterdam, Netherlands)|February 13, 2018
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-AnalysisEllen Westhoff, J Alfred Witjes, Neil E Fleshner, et al.
Bladder Cancer (Amsterdam, Netherlands)|February 13, 2018
Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder CancerTullika Garg, Jill Nault Connors, Ilene G Ladd, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 19, 2018
Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging?Alexander T Rozanski, Cooper R Benson, Jacob A McCoy, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 19, 2018
Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex VirusKwan Joong Joo, Hongtao Li, Xiaoliu Zhang, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 19, 2018
Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue?Günter Niegisch, Christina Hulsbergen-van de Kaa, Martine Ploeg, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 19, 2018
The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder CancerGarrett M Dancik, Dan Theodorescu
Bladder Cancer (Amsterdam, Netherlands)|August 27, 2025
Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancerHafdís Birta Johansson, Fredrik Liedberg, Carina Bernardo, et al.
Bladder Cancer (Amsterdam, Netherlands)|October 24, 2022
Urethral Melanoma - Clinical, Pathological and Molecular CharacteristicsRoy Mano, Benedikt Hoeh, Renzo G DiNatale, et al.
Bladder Cancer (Amsterdam, Netherlands)|October 8, 2021
A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder CancerRyan M Reyes, Emily Rios, Shane Barney, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 19, 2017
Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)Guido Dalbagni, Nicole Benfante, Daniel D Sjoberg, et al.
Pageof 31